Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29504171 | 1.00 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL14517806 | 1.00 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL4279811 | 1.00 | AR (0.68) | ARCYP2C19 | |
| SCHEMBL28379214 | 0.93 | AR (0.67) | AR | |
| SCHEMBL28379213 | 0.93 | AR (0.67) | AR | |
| SCHEMBL13167763 | 0.90 | AR (0.65) | AR | |
| SCHEMBL19243489 | 0.89 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL20113379 | 0.89 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL14878986 | 0.89 | AR (0.69) | ARCYP2C19 | |
| SCHEMBL5363230 | 0.89 | AR (0.69) | ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138353-A | Nicotinate hydrate and preparation method thereof | 宁波耆健医药科技有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-110981794-A | Synthetic method of nicotinate | 宁波耆健医药科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-12208141-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-29 | — | — | US | disclosed |
| US-12115146-B2 | Treatment of skeletal-related events for breast cancer patients | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240326697-A1 | SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | US | disclosed |
| US-12053448-B2 | Solid forms of selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240181066-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-26 | — | — | US | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-12 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-05-31 | — | — | US | disclosed |
| US-20070066568-A1 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066568-A1 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-03-22 | — | — | US | disclosed |
| WO-2007027582-A2 | TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027582-A2 | TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208141-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885CYP2C19 4495/4885 |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | AR 9/4885CYP2C19 4495/4885 |
| US-20240181066-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | AR 9/4885CYP2C19 4495/4885 |
| US-20070173546-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | AR 1/4885CYP2C19 2245/4885 |
| US-12115146-B2 | Treatment of skeletal-related events for breast cancer patients | AR, PGR, GNRHR | AR 1/4885CYP2C19 603/4885 |
| US-20070066568-A1 | Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators | AR, SARM1, OPRM1 | AR 1/4885CYP2C19 164/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885CYP2C19 848/4885 |
| US-20070123563-A1 | Selective androgen receptor modulators and method of use thereof | AR, SHBG, ESRRA | AR 1/4885CYP2C19 2245/4885 |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885CYP2C19 1798/4885 |
| US-20070161608-A1 | Selective androgen receptor modulators for treating muscle wasting | AR, ESRRA, SHBG | AR 1/4885CYP2C19 3467/4885 |
| US-12053448-B2 | Solid forms of selective androgen receptor modulators | AR, FSHR, NR5A1 | AR 1/4885CYP2C19 567/4885 |
| US-12202815-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, FSHR | AR 1/4885CYP2C19 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.